Great Point Partners Completes Growth Recapitalization of Velentium

Great Point Partners Recapitalizes SteriPack

June 17, 2019

Medical Devices

Great Point Partners completed a growth recapitalization of SteriPack to support the contract manufacturer's next phase of expansion and an aggressive add-on acquisition strategy. SteriPack, headquartered in Mullingar, Ireland, is a contract manufacturer and value‑added services provider to medical device and pharmaceutical customers with ~650 employees and facilities in Poland, Malaysia and the United States.

Great Hill Partners Completes Majority Recapitalization of Vatica Health

April 3, 2018

Healthcare Services

Great Hill Partners completed a majority recapitalization of Vatica Health, with participation from Vatica’s leadership team. The investment will support geographic expansion, sales and marketing growth, and product development to scale Vatica’s provider-centric risk adjustment and clinical quality platform.

HealthQuest Capital and Great Point Partners Invest Growth Equity in Cellipont Bioservices; Darren Head Named CEO

October 7, 2024

Biotechnology

Cellipont Bioservices named Darren Head as CEO and announced a minority growth equity investment from HealthQuest Capital, with majority investor Great Point Partners also participating. The capital and leadership transition are intended to support Cellipont’s expansion of cell-therapy CDMO capabilities and operational growth.

LLR Partners Leads Growth Investment in Viventium

February 7, 2023

Cloud & SaaS

LLR Partners has made a growth capital investment in Viventium, a SaaS-based human capital management and payroll platform focused on post-acute healthcare. Existing investor ABS Capital Partners and Viventium’s founders (the Kohn family) remain shareholders, and the capital will support continued product and customer growth; BMO Capital Markets served as lead financial advisor with KeyBanc as co-advisor.

Great Point Partners Makes Growth Investment in iXCells Biotechnologies

September 29, 2022

Biotechnology

Great Point Partners, a Greenwich, CT-based healthcare-focused private investment firm, has made a growth investment in San Diego-based iXCells Biotechnologies. The capital will be used to expand iXCells' operational capacity, broaden its product and service offering (including bioanalytical capabilities) and support growth into adjacent high-growth end markets such as personalized medicine and rare disease research.

Arlington Capital Partners Acquires Majority Stake in Riverpoint Medical

June 27, 2019

Medical Devices

Arlington Capital Partners completed a majority growth investment in Riverpoint Medical, a Portland-based developer and manufacturer of advanced biomedical textile medical devices. The investment will support Riverpoint's plans to expand manufacturing capacity, accelerate product development across wound closure, sports medicine and animal health markets, and scale the business with existing management retaining material ownership.